Weight Management in South Africa is entering a new phase as growing interest in GLP-1 medicines introduces different approaches to managing weight and obesity. Traditionally associated with meal replacements, slimming supplements and lifestyle changes, the category is increasingly being influenced by prescription treatments that target appetite regulation and support weight loss. Medicines such as Wegovy and Mounjaro have gained attention locally, creating new conversations around treatment options, accessibility and nutritional support.
Recent developments illustrate how South Africa’s GLP-1 market is evolving. In July 2026, the South African Health Products Regulatory Authority (SAHPRA) confirmed that it had 12 applications for generic semaglutide medicines under review, while Novo Nordisk announced plans to introduce a lower-cost authorised version of Ozempic, known as Extensior. These developments could increase competition and improve access to GLP-1 treatments, although affordability remains an important consideration for consumers.
The growing prominence of medical Weight Management is also creating opportunities beyond prescription treatment. As GLP-1 medicines influence appetite and food intake, nutritional considerations such as protein consumption, fibre intake and hydration are becoming relevant areas of support. South African healthcare researchers have emphasised that obesity treatment requires a broader approach incorporating nutrition, physical activity and appropriate medical treatment. This creates opportunities for established Weight Management brands to position nutritional products alongside wider health and wellness routines.
Local product activity reflects this development. In July 2026, Slimz South Africa introduced its GLP-1 Weight Management range, comprising Metabolic Peptide Support Capsules, Digestive Fibre Support Shakes, Electrolyte Support Sachets and a Protein + Collagen Peptide Support Shake. Youthful Living’s Body Fit range also includes GL1-Lean Booster and GL1-Lean Meal Support. Meanwhile, Clicks stocks the Drops GLP-1 Support System, which combines fibre, protein and hydration products marketed for consumers using GLP-1 medicines.
This growing overlap between pharmaceutical treatments and nutritional supplements highlights the importance of clear product positioning. GLP-1-related supplements are distinct from prescription GLP-1 medicines and should not be regarded as equivalent treatments. Separately, in May 2026, SAHPRA and the South African Pharmacy Council intensified enforcement against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines.
For South African Weight Management brands, these developments highlight opportunities to remain relevant as consumers explore different treatment approaches. While prescription medicines represent a distinct part of the healthcare market, growing attention to nutritional support, convenience and ongoing wellbeing creates opportunities for complementary products to address specific consumer needs.
As the Weight Management landscape evolves, brands that communicate product benefits clearly, distinguish nutritional support from medical treatment and respond to changing consumer needs may be better positioned to navigate the market. GLP-1 medicines are unlikely to eliminate conventional Weight Management products, but their growing prominence could influence how the broader category develops, with increasing attention given to medical treatment, nutrition and sustainable lifestyle management.
Spotlight; IOL; Reuters; South African Journal of Surgery; Clicks; SAHPRA
